ArticleCureus2025
Impact of Filgrastim on Mortality During Induction Chemotherapy in Childhood B-Cell Non-Hodgkin Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Survival Patterns in Childhood B-Cell Non-Hodgkin Lymphoma in Resource-Constrained Countries.Journal of cancer & allied specialties · 2026Article
- Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Childhood B-cell non-Hodgkin lymphoma (NHL) is a group of rapidly growing neoplasms that are fatal if left untreated. Induction chemotherapy during the treatment makes these patients vulnerable to several life-threatening infections due to their immunocompromised state. Prophylactic use of filgrastim before initiating the second induction chemotherapy cycle can improve outcomes. Therefore, our study aims to assess various parameters that can lead to acute mortality during induction chemotherapy and how the prophylactic use of filgrastim can prevent it. Methods This retrospective study was performed at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. All patients of B-cell NHL under 10 years of age diagnosed between January 2018 and October 2021 were included. Various parameters including patient age, stage of disease, treatment regimen, day of the start of filgrastim, number of episodes of febrile neutropenia, duration of admission in hospital due to febrile neutropenia, day of count recovery, and outcomes were collected. Results Of the 106 patients, 45 (42.4%) were female and 61 (57.5%) were male; 60 patients (56.7%) were between one and five years of age. All patients were started on granulocyte colony-stimulating factor (G-CSF) on the seventh day of the first induction chemotherapy cycle. A total of 97 patients (91.5%) remained alive until the end of induction, and nine patients (8.5%) succumbed due to febrile neutropenia complications. The median days for filgrastim were eight (0-20) days after completion of the first cycle of COPADM (cyclophosphamide, vincristine, prednisolone, doxorubicin, and methotrexate). On applying the Mann-Whitney U test, there was a significant difference in the day of count recovery among infected and non-infected patients (p = 0.01). Conclusions Primary prophylactic use of filgrastim can significantly reduce mortality during induction chemotherapy in childhood B-cell NHL. Patients had lower febrile neutropenia episodes, decreased length of hospital stay, and, early count recovery. Therefore, filgrastim before the second cycle of induction chemotherapy, especially in resource-limited settings, can yield better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.